Minimum Inhibitory Concentration

How to Cite

Moshafi, M. H., Peymani, A., Foroumadi, A., Zabihi, M. R., & Doostishoar, F. (2019). Antibacterial Activities of 5-Nitro-2-uryl and 5-Nitro-2-Imidazolyl Derivatives of 1,3,4-Thiadiazole. Internal Medicine and Medical Investigation Journal, 4(2). https://doi.org/10.24200/imminv.v4i2.213


Introduction: Nitrofurans and nitroimidazoles are broad-spectrum antimicrobial agents, which affect the microbial DNA. The aim of the present study was to evaluate the new derivatives of these two groups of antimicrobials against certain Gram-positive and Gram-negative bacterial strains. Materials and Methods: Seven new derivatives of nitrofurans and nitroimidazoles were synthesized, and 6.4 mg of each derivative was dissolved in dimethyl sulfoxide. Then, 8 serial dilutions (0.5, 1, 2, 4, 8, 16, 32, and 64 μg/ml) of each derivative was prepared using Muller-Hinton broth, and the minimum inhibitory concentration for each derivative was measured and compared to ciprofloxacin (standard). Results: All the derivatives had no antibacterial effects against Gram-negative bacteria (minimum inhibitory concentration > 64 μg/ml); only 2-(5-nitro-2-furyl)-5-(n-pentylsulfunyl)-1,3,4-thiadiazole exhibited mild antibacterial effects against Klebsiella pneumonia (minimum inhibitory concentration of 16-32 μg/ml). The antibacterial effects of the derivatives against Gram-positive bacteria also showed variations from complete inhibition of the growth of Staphylococcus epidermidis and Bacillus subtilis (minimum inhibitory concentration < 0.5 μg/ml) by 2-(5-nitro-2-furyl)-5-(n-buthylthio)-1,3,4-thiadiazole to no inhibition of S. epidermidis and streptococcus pyogenes. Conclusion: These compounds have weak antibacterial effects; only two derivatives showed antibacterial effects similar to that of the positive control.



Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. Pharm Ther. 2015;40(4):277-83.

Marston HD, Dixon DM, Knisely JM, Palmore TN, Fauci AS. Antimicrobial resistance. JAMA. 2016;316(11):1193-204.

Mardani M, Afra SM, Tanideh N, Andisheh Tadbir A, Modarresi F, Koohi-Hosseinabadi O, et al. Hydroalcoholic extract of Carum carvi L. in oral mucositis: a clinical trial in male golden hamsters. Oral Dis. 2016;22(1):39-45.

Moshafi MH, Doostishoar F, Jahanian A, Abaszadeh M. Antimicrobial effects of new designed 2-amino-tetrahydro-4H-chromene-3-carbonitrile derivatives against some pathogenic microbial strains. Comp Clin Path. 2016;25(6):1197-200.

Rusen E, Diacon A, Mocanu A, Rizea F, Bucur B, Bucur MP, et al. Synthesis and retention properties of molecularly imprinted polymers for antibiotics containing a 5-nitrofuran ring. RSC Adv. 2017;7(80):50844-52.

Guay DR. An update on the role of nitrofurans in the management of urinary tract infections. Drugs. 2001;61(3):353-64.

Muller M. Reductive activation of nitroimidazoles in anaerobic microorganisms. Bioreduction in the Activation of Drugs: Proceedings of the Second Biochemical Pharmacology Symposium, Oxford, UK, 25-26 July 1985;35(1):37-41 (2013: Elsevier).

Edwards DI. Reduction of nitroimidazoles in vitro and DNA damage. Bioreduction in the Activation of Drugs: Proceedings of the Second Biochemical Pharmacology Symposium, Oxford, UK, 25-26 July 1985;35(1):53-86 (2013 Elsevier).

Jain AK, Sharma S, Vaidya A, Ravichandran V, Agrawal RK. 1, 3, 4-Thiadiazole and its Derivatives: A Review on Recent Progress in Biological Activities. Chem Biol Drug Des. 2013;81(5):557-76.

Eloff JN. A sensitive and quick microplate method to determine the minimal inhibitory concentration of plant extracts for bacteria. Planta Med. 1998;64(08):711-3.

Wiegand I, Hilpert K, Hancock RE. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc. 2008;3(2):163-75.

Ryan K, Ray C. Sherris Medical Microbiology. London: McGraw Hill. 2000; 2000.

Mather R Karenchak LM Romanowski EG Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463–66.

Garg P Sharma S Rao GN. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmol. 1999;106:1319–23.

Dizaj SM, Mennati A, Jafari S, Khezri K, Adibkia K. Antimicrobial activity of carbon-based nanoparticles. Adv Pharm Bull. 2015;5(1):19-23.

Al-Jumaili A, Alancherry S, Bazaka K, Jacob M. Review on the antimicrobial properties of carbon nanostructures. Materials. 2017;10(9):1066.

Koohi-Hosseinabadi O, Moini M, Safarpoor A, Derakhshanfar A, Sepehrimanesh M. Effects of dietary Thymus vulgaris extract alone or with atorvastatin on the liver, kidney, heart, and brain histopathological features in diabetic and hyperlipidemic male rats. Comp Clin Path. 2015;24(6):1311-5.

Foroumadi A, Mirzaei M, Shafiee A. Antituberculosis agents II. Evaluation of in vitro antituberculosis activity and cytotoxicity of some 2-(1-methyl-5-nitro-2-imidazolyl)-1, 3, 4-thiadiazole derivatives. Farmaco. 2001;56(8):621-3.

Foroumadi A, Asadipour A, Mirzaei M, Karimi J, Emami S. Antituberculosis agents. V. Synthesis, evaluation of in vitro antituberculosis activity and cytotoxicity of some 2-(5-nitro-2-furyl)-1, 3, 4-thiadiazole derivatives. Farmaco. 2002;9(57):765-9.

Foroumadi A, Soltani F, Moshefi M, Ashraf-Askari R. Synthesis and in vitro antibacterial activity of some n-(5-aryl-1, 3, 4-thiadiazole-2-yl) piperazinyl quinolone derivatives. Farmaco. 2003;58(10):1023-8.

Alireza F, Mohsen D, Abbas S. Synthesis and in vitro antifungal activity of 2-aryl-5-phenylsulfonyl-1, 3, 4-thiadiazole derivatives. Arzneimittelforschung. 1999;49(12):1035-8.

Foroumadi A, Kargar Z, Sakhteman A, Sharifzadeh Z, Feyzmohammadi R, Kazemi M, et al. Synthesis and antimycobacterial activity of some alkyl [5-(nitroaryl)-1, 3, 4-thiadiazol-2-ylthio] propionates. Bioorg Med Chem Lett. 2006;16(5):1164-7.

Foroumadi A, Soltani F, Jabini R, Moshafi MH, Rasnani FM. Antituberculosis agents x. synthesis and evaluation of in vitro antituberculosis activity of 2-(5-nitro-2-furyl)-and 2-(1-methyl-5-nitro-1H-imidazol-2-yl)-1, 3, 4-thiadiazole derivatives. Arch Pharm Res. 2004;27(5):502-6.

Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev. 2003;23(2):146-89.

Abdel-Wahab BF, Abdel-Aziz HA, Ahmed EM. Synthesis and antimicrobial evaluation of some 1, 3-thiazole, 1, 3, 4-thiadiazole, 1, 2, 4-triazole, and 1, 2, 4-triazolo [3, 4-b][1, 3, 4]-thiadiazine derivatives including a 5-(benzofuran-2-yl)-1-phenylpyrazole moiety. Monatsh Chem. 2009;140(6):601-5.

Padmavathi V, Reddy GD, Reddy SN, Mahesh K. Synthesis and biological activity of 2-(bis ((1, 3, 4-oxadiazolyl/1, 3, 4-thiadiazolyl) methylthio) methylene) malononitriles. Euro J Med Chem. 2011;46(4):1367-73.

Kadi AA, Al-Abdullah ES, Shehata IA, Habib EE, Ibrahim TM, El-Emam AA. Synthesis, antimicrobial and anti-inflammatory activities of novel 5-(1-adamantyl)-1, 3, 4-thiadiazole derivatives. Eur J Med Chem. 2010;45(11):5006-11.

Serban G, Stanasel O, Serban E, Bota S. 2-Amino-1, 3, 4-thiadiazole as a potential scaffold for promising antimicrobial agents. Drug Des Devel Ther. 2018;12:1545-66.

Foroumadi A, Mirzaei M, Shafiee A. Antituberculosis agents II. Evaluation of in vitro antituberculosis activity and cytotoxicity of some 2-(1-methyl-5-nitro-2-imidazolyl)-1, 3, 4-thiadiazole derivatives. Farmaco. 2001;56(8):621-3.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.